CI · Cigna Group

167 filings

CI SEC Filings

Cigna Group - 167 total filings

Filing record · 2018–202610-K810-Q238-K136

Showing 1–50 of 167 filings

Cigna Group 8-K Report, Executive Changes (Oct 9, 2026)

The Cigna Group (CI) has announced a significant change to its Board of Directors. Donna F. Zarcone has informed the Board of her intention to retire as a director effective December 31, 2026. This development, detailed in an 8-K filing dated October 9, 2026, is presented as a planned retirement and is not attributed to any disputes or disagreements with the company. While the departure itself may not have an immediate operational impact, investors often scrutinize board composition and leadership transitions. Ms. Zarcone's retirement signifies a shift in the Board's experience and perspectives. Investors should monitor the company's subsequent announcements regarding the election of new directors or adjustments to committee memberships to understand the ongoing governance strategy and ensure continued oversight and strategic guidance for The Cigna Group.

Oct 9, 2026 8-K

Cigna Group 8-K Report, Regulation FD Disclosure (Sep 30, 2026)

The Cigna Group (CI) furnished an 8-K on September 30, 2026 tied to its 2026 Investor Day, in which it reaffirmed full-year 2026 guidance rather than changing it. Management expects consolidated adjusted revenues of about $280 billion, adjusted EPS of at least $30.45, Evernorth Health Services adjusted income from operations of at least $6.9 billion, Cigna Healthcare adjusted income from operations of at least $4.55 billion, and a Cigna Healthcare medical care ratio of 83.7% to 84.7%. The reaffirmation signals stability in the current outlook, which was previously set in the July 30, 2026 earnings release. The main new information is strategic and long-term. Management introduced a "Lead to One" vision centered on personalization at scale and complex care leadership, and announced 2026–2030 targets of a 10–14% adjusted EPS CAGR and roughly $50 billion in cumulative operating cash flow. It also unveiled a new $3 billion multi-year modernization and productivity program intended to be self-funding, focused on process streamlining, AI-enabled tools, and supplier/vendor management. Investors will want to assess whether this program delivers net margin improvement without disrupting operations. The filing also reiterates that the outlook excludes the effects of any business combinations after the report date, and includes expected share repurchases and 2026 dividends. Forward-looking statements carry standard risks, including medical cost trends, drug pricing and pharmacy marketplace shifts, government program exposure, regulatory changes, and cyber and AI-related risks. The 10–14% EPS growth target and cash flow goals are multi-year aspirations that depend on execution and external conditions, so they should be weighed with appropriate caution.

Sep 30, 2026 8-K

Cigna Group 8-K Report, Financial Results (Jul 30, 2026)

The Cigna Group (CI) reported second quarter 2026 results on July 30, 2026, with total revenues up 7% year over year to $71.7 billion and shareholders' net income of $1.7 billion, or $6.29 per share, versus $5.71 in Q2 2025. Adjusted income from operations rose 6% to $2.1 billion, or $7.78 per share, versus $7.20 a year earlier. The growth was driven mainly by Cigna Healthcare, where adjusted pre-tax income increased 17% on an improved U.S. Employer margin, while Evernorth Health Services' adjusted pre-tax income fell 2% as Pharmacy Benefit Services declined 27% on client and customer-focused initiatives. Specialty and Care Services grew adjusted pre-tax income 22%. Management raised its full-year 2026 adjusted income from operations outlook to at least $30.45 per share, up $0.10, and increased the Cigna Healthcare pre-tax outlook by $25 million to at least $4.55 billion. The Evernorth pre-tax outlook is at least $6.9 billion, and the Cigna Healthcare medical care ratio is guided to 83.7% to 84.7%. The SG&A expense ratio improved to 4.8% from 5.1%, reflecting operating efficiency. The quarter also showed some top-line pressure. Total customer relationships fell 3% from year-end 2025 to 182.8 million, driven by a 4% decline in pharmacy customers from expected client transitions and lower health plan membership. Medical customers grew 2% to 18.4 million. The company also announced in April 2026 its planned exit from the Individual and Family Plans medical business effective January 1, 2027. Through July 29, 2026, it repurchased 0.9 million shares for about $250 million.

Jul 30, 2026 10-Q

Cigna Group Quarterly Report for Q2 Ended Jun 30, 2026

The Cigna Group's Q2 2026 10-Q shows a quarter of solid top-line and earnings growth, led by Cigna Healthcare. Total revenues rose 7% to $71.7 billion for the quarter and 6% to $140.2 billion for the six months. Shareholders' net income grew 8% to $1.66 billion ($6.29 diluted EPS, up 10%), and adjusted income from operations rose 6% to $2.05 billion ($7.78 adjusted EPS, up 8%). Growth was driven mainly by Cigna Healthcare, where pre-tax adjusted income rose 17% on better U.S. Employer margins and premium rate increases, while Evernorth was flat for the half year (-2% in the quarter) as Pharmacy Benefit Services income fell 27% on client- and customer-focused initiatives, partly offset by Specialty and Care Services growth of 22%. The balance sheet and cash flow picture is more mixed. Operating cash flow was only $710 million for the first six months versus $34 million a year earlier, but this was largely driven by working-capital timing and factoring facilities, and pharmacy payables fell $4.1 billion. Short-term debt rose to $2.8 billion from $0.6 billion, while long-term debt declined to $29.1 billion. The debt-to-capitalization ratio improved slightly to 42.8% from 43.0%. Capital returns were much lighter than last year, with $250 million of buybacks versus $2.6 billion in the prior-year period, and quarterly dividends were maintained at $1.56 per share. Other comprehensive loss of $1.6 billion for the half year, driven by discount-rate changes on long-duration liabilities, pushed accumulated other comprehensive loss to $4.4 billion. Investors should also note the April 2026 announced exit from the Individual and Family Plans medical business effective January 1, 2027, a $450 million strategic optimization program cost year-to-date (program costs expected to continue through 2028), and litigation charges of $77 million in the quarter. The HCSC divestiture of Medicare Advantage in March 2025 continues to depress year-over-year comparisons for premiums and medical costs.

Jul 30, 2026 8-K

Cigna Group 8-K Report, Regulation FD Disclosure (May 13, 2026)

The Cigna Group (CI) has issued an 8-K filing on May 13, 2026, to reaffirm its previously issued full-year 2026 outlook. During upcoming investor meetings, company officials expect to confirm their projected consolidated adjusted income from operations on a per-share basis of at least $30.35. This affirmation signals management's confidence in the company's ongoing performance and its ability to meet financial targets for the year. The filing also provides a definition of consolidated adjusted income from operations, a key non-GAAP metric used by management to assess underlying business performance. While the company is unable to provide a GAAP reconciliation for this forward-looking metric due to the unpredictable nature of certain components like investment gains/losses and special items, investors should note that this measure is distinct from GAAP shareholders' net income. The reaffirmation of guidance is a significant data point for investors as they evaluate The Cigna Group's financial trajectory and operational stability.

May 13, 2026 8-K

Cigna Group 8-K Report, Financial Results (Apr 30, 2026)

The Cigna Group (NYSE: CI) reported first quarter 2026 results on April 30, 2026, showing growth in both GAAP and adjusted earnings and raising its full-year 2026 outlook. Shareholders' net income rose to $1.7 billion, or $6.26 per share, from $1.3 billion, or $4.85 per share, a year earlier. Adjusted income from operations increased 12% to $2.1 billion, or $7.79 per share, versus $6.74 in Q1 2025. Total revenues grew 5% to $68.5 billion, driven by Evernorth Health Services, though the divestiture of Medicare businesses to HCSC reduced Cigna Healthcare revenues by 21% year over year. The quality of earnings growth was mixed by segment. Cigna Healthcare was the primary driver, with adjusted pre-tax income up 18% to $1.51 billion and its medical care ratio improving to 79.8% from 82.2%, aided largely by the HCSC transaction. Excluding that divestiture, Cigna Healthcare adjusted revenues rose 8%, supported by premium rate increases. Evernorth Health Services adjusted pre-tax income rose only 2%, with Pharmacy Benefit Services down 28% on expected lower contributions from large clients, partially offset by 20% growth in Specialty and Care Services. Pharmacy customer relationships declined 2% sequentially, while medical customers rose 1%. Management raised its 2026 adjusted EPS outlook to at least $30.35 from $30.25, and raised the Cigna Healthcare pre-tax outlook by $25 million to at least $4.525 billion. The Evernorth pre-tax outlook was reaffirmed at at least $6.9 billion, and the Cigna Healthcare MCR outlook is 83.7% to 84.7%. The debt-to-capitalization ratio improved to 42.3% from 43.0% at year-end 2025, and the SG&A expense ratio fell to 5.4% from 6.4%. Investors should note that the guidance excludes future acquisitions and that a meaningful portion of year-over-year improvement reflects portfolio changes rather than organic growth.

Apr 30, 2026 10-Q

Cigna Group Quarterly Report for Q1 Ended Mar 31, 2026

Cigna Group reported strong financial results for the first quarter of 2026, with total revenues reaching $68.5 billion, a 5% increase year-over-year, driven primarily by an 11% rise in Pharmacy revenues and a 14% increase in Fees and other revenues. Shareholders' net income saw a significant jump of 25% to $1.65 billion, or $6.26 per diluted share, reflecting improved operational performance across its segments. The Evernorth Health Services segment demonstrated robust growth, with adjusted revenues up 9%, propelled by strong performance in Pharmacy Benefit Services. The Cigna Healthcare segment, despite a 21% decline in adjusted revenues primarily due to the prior year's HCSC transaction, achieved an impressive 18% increase in pre-tax adjusted income from operations, signaling margin expansion. Overall, the company's strategic focus on its health services capabilities appears to be yielding positive results, with solid revenue growth and a substantial increase in profitability.

Apr 30, 2026 8-K

Cigna Group 8-K Report, Shareholder Vote Results (Apr 27, 2026)

Cigna Group's 8-K reports the results of its Annual Meeting of Shareholders held April 22, 2026. Holders of 237,225,441 shares, or 89.97% of the 263,660,761 shares outstanding and entitled to vote, were represented. The filing is procedural and contains no financial results, guidance, or operating metrics. All twelve director nominees were elected to one-year terms. Support ranged from roughly 94.6% (Eric J. Foss, about 207.6 million for versus 11.8 million against) to about 97% for David M. Cordani, based on votes for and against. Shareholders also approved the advisory say-on-pay resolution on executive compensation, with about 201.7 million votes for and 17.4 million against (about 92% for). They ratified PricewaterhouseCoopers LLP as the independent registered public accounting firm for 2026, with about 216.1 million votes for and 21.0 million against. A shareholder proposal to let shareholders act by written consent failed, with about 105.0 million votes for and 114.2 million against. For investors, the results signal broad board and management support, a meaningful but not dominant share of votes for the say-on-pay proposal, and a shareholder base that did not back the written-consent governance change at this meeting.

Apr 27, 2026 8-K

Cigna Group 8-K Report, Executive Changes (Mar 3, 2026)

The Cigna Group (CI) announced a planned CEO transition: Board-appointed President & COO Brian C. Evanko will succeed David M. Cordani as Chief Executive Officer effective July 1, 2026, with Cordani becoming Executive Chair. Evanko, 49, has held senior roles across the company including CFO (2021-2024), CEO of Cigna Healthcare (2024-2025), and President & COO since March 2025, giving investors continuity from an internally developed successor. Evanko also joins the Board as a director effective April 1, 2026, which expands the Board to twelve members, and Eric J. Foss becomes Lead Independent Director on the same date, succeeding Eric C. Wiseman, who moves to chair the Corporate Governance Committee. Committee assignments were reshuffled effective April 1, 2026. Compensation for the incoming CEO is set at a $1.3 million base salary, a $2.6 million EIP target, and a $15.1 million annual LTI target, weighted 60% performance shares, 25% restricted stock, and 15% options. A one-time $3.5 million Transitional Equity Award is contingent on him assuming the CEO role. Cordani's Executive Chair pay is $1.0 million base and a $2.0 million EIP target, and his 2026-2028 SPS award can continue vesting after retirement if he remains in service one year from grant and complies with restrictive covenants. Separately, under Regulation FD, Cigna reaffirmed its 2026 outlook: consolidated adjusted income from operations of at least $30.25 per share, Evernorth pre-tax adjusted income from operations of at least $6.9 billion, and Cigna Healthcare pre-tax adjusted income from operations of at least $4.5 billion. Because the guidance was reiterated rather than changed, the leadership transition does not by itself alter the company's near-term earnings expectations.

Mar 3, 2026 8-K

Cigna Group 8-K Report, Regulation FD Disclosure (Feb 27, 2026)

The Cigna Group (CI) filed an 8-K on February 27, 2026, primarily to reaffirm its previously issued 2026 financial outlook. Management expects to participate in investor and analyst meetings and will reiterate their projection of full-year consolidated adjusted income from operations on a per-share basis to be at least $30.25. This reaffirmation suggests management's continued confidence in the company's performance and its ability to achieve its previously stated financial goals for the year. Investors should note that this information is being provided under Regulation FD Disclosure. The company also provides a definition and rationale for using 'adjusted income from operations' as a key performance metric, highlighting its exclusion of certain items like net investment gains/losses and special items to present a clearer view of underlying business results. Management also states they cannot provide a GAAP reconciliation for future periods due to the unpredictable nature of certain excluded items, such as investment results and special items.

Feb 27, 2026 10-K

Cigna Group Annual Report, Year Ended Dec 31, 2025

The Cigna Group's 2025 10-K filing highlights a strong financial performance, with shareholders' net income increasing by 73% year-over-year, primarily driven by the absence of a prior year impairment charge. Adjusted income from operations also saw a healthy 4% increase, reflecting the company's ongoing operational efficiency and strategic initiatives. The divestiture of its Medicare Advantage and related businesses to HCSC in March 2025 contributed to a decrease in medical customers but also led to a significant cash inflow and strategic realignment. Evernorth Health Services continues to be a strong performer, with adjusted revenues up 16% and pre-tax adjusted income from operations increasing by 3%, driven by growth in Pharmacy Benefit Services and Specialty and Care Services. Cigna Healthcare experienced a revenue decline of 11%, largely due to the HCSC divestiture, though the ongoing U.S. Healthcare businesses saw improvement in premiums. The company is also investing in innovation, including a rebate-free pharmacy benefits model, which is expected to impact short-term earnings but enhance long-term value and transparency.

Feb 26, 2026 8-K

Cigna Group 8-K Report, Financial Results (Feb 5, 2026)

The Cigna Group (CI) reported fourth quarter and full year 2025 results on February 5, 2026, showing continued growth in its Evernorth Health Services segment, which drove total revenues up 11% for the year to $274.9 billion. Shareholders' net income for 2025 was $6.0 billion, or $22.18 per share, versus $3.4 billion ($12.12 per share) in 2024, which had been depressed by a one-time $2.7 billion after-tax investment loss. Adjusted income from operations, the company's primary profitability measure, rose 4% to $8.0 billion, or $29.84 per share, and fourth quarter adjusted income grew 16% year over year to $2.1 billion ($8.08 per share). Segment results were mixed beneath the headline numbers. Evernorth's adjusted pre-tax income grew 3% for the year, with Pharmacy Benefit Services profit declining 2% due to strategic investments despite 18% revenue growth, while Specialty and Care Services grew profit 8%. Cigna Healthcare's full-year pre-tax income fell 2%, and its medical care ratio deteriorated to 84.4% from 83.2%, largely due to the Individual and Family Plans business; revenue declines reflected the March 2025 divestiture of the Medicare businesses to HCSC. Fourth quarter Cigna Healthcare profit rose 44%, helped by stop-loss results. For 2026, management guided to adjusted revenues of approximately $280.0 billion, adjusted income from operations of at least $7.95 billion ($30.25 per share), and Evernorth pre-tax income of at least $6.9 billion, while Cigna Healthcare pre-tax income is guided to at least $4.5 billion with an MCR of 83.7% to 84.7%. The board also raised the quarterly dividend to $1.56 per share from $1.51, and the company repurchased 11.9 million shares for about $3.6 billion in 2025, lowering the debt-to-capitalization ratio to 43.0%.

Feb 5, 2026 8-K

Cigna Group 8-K Report, Corporate Update (Nov 18, 2025)

The Cigna Group (CI) has filed an 8-K detailing significant changes to its Board of Directors' committee structure, effective January 1, 2026. These adjustments are a proactive response to the evolving health services industry and aim to enhance corporate governance and strategic alignment. The primary changes involve the dissolution of the standalone Compliance Committee, with its responsibilities being absorbed by other committees and the full Board. This reflects a strategic streamlining following the divestiture of certain Medicare businesses earlier in 2025. Investors should note that while compliance oversight remains a priority, its structure is being reorganized for greater efficiency and integration with broader company strategy. The Audit Committee will be renamed the "Audit and Compliance Committee" to incorporate oversight of enterprise compliance matters. The Corporate Governance Committee will gain responsibility for the company's ethics program and public clinical reporting. Crucially, oversight of clinical compliance, including patient experience, will now fall under the purview of the full Board, emphasizing its strategic importance. Furthermore, technology oversight, encompassing areas like AI, cybersecurity, and business continuity, will be consolidated under the Finance Committee, which will be renamed the "Finance and Technology Committee." These changes signal a commitment to adapting governance to the company's current strategic focus and operational landscape.

Nov 18, 2025 10-Q

Cigna Group Quarterly Report for Q3 Ended Sep 30, 2025

The Cigna Group reported a significant increase in net income for the nine months ended September 30, 2025, driven by the absence of a substantial prior-year investment impairment. Total revenues grew by 12% year-over-year, largely due to strong performance in Pharmacy revenues, which increased by 17%. This growth was primarily fueled by higher utilization and customer expansion within the Evernorth Health Services segment. However, the Cigna Healthcare segment experienced a revenue decline of 9%, largely attributable to the divestiture of its Medicare Advantage business. Despite this, the company managed its expenses effectively, with Selling, General, and Administrative (SG&A) expenses remaining relatively flat year-over-year when excluding the impact of strategic optimization programs. The company also strengthened its balance sheet by issuing new senior notes and repaying existing debt, demonstrating a proactive approach to capital management.

Oct 30, 2025 8-K

Cigna Group 8-K Report, Financial Results (Oct 30, 2025)

The Cigna Group (CI) reported third quarter 2025 results on October 30, 2025, with total revenues up 10% year over year to $69.7 billion, driven primarily by Evernorth Health Services and strong specialty pharmacy growth. GAAP shareholders' net income was $1.9 billion, or $6.98 per share, versus $0.7 billion, or $2.63 per share, in the prior-year quarter, which included a $1.0 billion after-tax investment loss. Adjusted income from operations was $2.1 billion, or $7.83 per share, roughly flat with the $7.51 reported a year earlier, and adjusted operating income declined 1% year over year. The segment picture is mixed. Evernorth Health Services grew adjusted revenues 15% and adjusted pre-tax income 1%, with Pharmacy Benefit Services revenues up 18% but profit down 6% due to strategic investments, while Specialty and Care Services profit rose 11%. Cigna Healthcare faced pressure: adjusted pre-tax income fell 12% and the medical care ratio rose to 84.8% from 82.8%, driven by the Individual and Family Plans business and higher stop-loss costs. Adjusted revenues in that segment fell 18% largely because of the March 2025 divestiture of Medicare businesses to HCSC, though growth was 6% excluding that impact. Management reaffirmed full-year 2025 adjusted EPS of at least $29.60 and guided to Cigna Healthcare MCR of 83.2% to 84.2%. The company also announced a new rebate-free pharmacy benefit model, which is a strategic initiative that could affect future Evernorth economics and warrants monitoring for its financial impact.

Oct 30, 2025 8-K

Cigna Group 8-K Report, Executive Changes (Oct 20, 2025)

The Cigna Group (CI) has filed an 8-K report indicating the upcoming retirement of a long-standing Board member, Retired Major General Elder Granger, M.D. The retirement is scheduled to take effect on December 31, 2025. This departure aligns with the company's established retirement age policy and is explicitly stated to be free of any disagreements between Dr. Granger and the Company. While the departure of a board member can sometimes signal underlying issues, the disclosed reasons here suggest a planned and orderly transition, which is a positive indicator for corporate governance and stability.

Oct 20, 2025 8-K

Cigna Group 8-K Report, Material Agreement (Sep 4, 2025)

The Cigna Group (CI) has announced the successful completion of a significant debt offering totaling $4.5 billion. The offering comprised four tranches of senior notes with varying maturities and interest rates, ranging from 4.500% for the 2030 Notes to 6.000% for the 2056 Notes. This issuance is primarily aimed at repaying $2.0 billion of outstanding loans, which were used to fund a strategic investment in another company. The remaining proceeds will be allocated towards general corporate purposes, including potential future investments and debt repayment.

Sep 4, 2025 8-K

Cigna Group 8-K Report, Regulation FD Disclosure (Sep 2, 2025)

The Cigna Group (CI) issued a current report on Form 8-K on September 1, 2025, to affirm its previously issued full-year 2025 outlook. The company expects to achieve consolidated adjusted income from operations on a per-share basis of at least $29.60. This affirmation comes as company officials are scheduled to participate in investor and analyst meetings over the coming weeks, providing an opportunity to reiterate key financial projections. While the company is reaffirming its guidance, it's important for investors to note that this disclosure does not introduce new financial targets. The full 2025 outlook was initially communicated on July 31, 2025. The report also includes a standard disclaimer regarding forward-looking statements and the inherent uncertainties and risks associated with achieving these projections. Investors are encouraged to review the company's website for further details on the outlook and the associated risks.

Sep 2, 2025 10-Q

Cigna Group Quarterly Report for Q2 Ended Jun 30, 2025

The Cigna Group reported solid financial results for the six months ended June 30, 2025, demonstrating resilience and strategic execution. Total revenues increased by 13% year-over-year, reaching $132.68 billion, primarily driven by a significant 17% surge in Pharmacy revenues, fueled by customer growth in Evernorth Health Services. This strong top-line performance, coupled with disciplined cost management, resulted in a substantial 125% increase in Shareholders' Net Income to $2.86 billion, largely benefiting from the absence of a significant prior-year equity impairment. The company also successfully completed the divestiture of its Medicare Advantage and related businesses to HCSC, strengthening its strategic focus and financial position. Operationally, the company continues to execute its growth strategies across its Evernorth Health Services segment, which saw a 16% increase in adjusted revenues. While the Cigna Healthcare segment experienced an 18% decrease in adjusted revenues for the quarter due to the HCSC transaction, the underlying U.S. Healthcare businesses showed premium growth. The company maintained a strong liquidity position with significant undrawn committed capacity and a robust cash flow from operations, enabling continued capital deployment through dividends and share repurchases. Management remains confident in the company's ability to navigate market dynamics and deliver long-term shareholder value.

Jul 31, 2025 8-K

Cigna Group 8-K Report, Financial Results (Jul 31, 2025)

The Cigna Group (CI) reported second quarter 2025 results on July 31, 2025, with total revenues up 11% year over year to $67.2 billion, driven mainly by Evernorth Health Services. Shareholders' net income was $1.5 billion, or $5.71 per diluted share, versus $5.45 a year earlier. Adjusted income from operations was $1.9 billion, or $7.20 per share, up about 1% from $6.72, and management reaffirmed full-year 2025 adjusted EPS of at least $29.60. The quality of growth is mixed. Evernorth's adjusted pre-tax income rose 5% and its pre-tax margin fell to 2.9% from 3.3%, reflecting a shift toward lower-margin pharmacy revenue. Cigna Healthcare's adjusted revenues fell 18%, largely because of the March 2025 divestiture of Medicare businesses to HCSC, while its MCR rose to 83.2% from 82.3% on higher stop-loss medical costs. Excluding the divestiture, Cigna Healthcare revenue grew about 7%. Share count reduction is a meaningful driver of per-share results. Weighted average shares fell to 268.2 million from 284.1 million, and the per-share growth rate outpaced the growth in net income. Corporate and Other losses narrowed to $357 million from $451 million. The SG&A expense ratio improved to 5.1% from 6.1%, which the company attributed to business mix and revenue growth. Total customer relationships were 182.2 million, with medical customers down 6% mainly because of the HCSC transaction. For investors, the key points are that the reaffirmed outlook implies limited upside from the second quarter run rate. Medical cost pressure in Cigna Healthcare and the thin Evernorth margin are the main watch items. The filing is a furnished 8-K, so the press release is not deemed filed under the Exchange Act.

Jul 31, 2025 8-K

Cigna Group 8-K/A Report, Executive Changes (Jul 28, 2025)

The Cigna Group (CI) has filed an amendment to its prior 8-K filing to provide updated information regarding the committee appointments of a newly appointed Board member. Michael J. Hennigan, who was appointed to the Board effective June 2, 2025, has now been assigned to serve on both the Audit Committee and the Corporate Governance Committee. This amendment clarifies the initial filing which noted that committee assignments were pending at the time of his appointment. For investors, these committee assignments are significant as they indicate Mr. Hennigan's involvement in key oversight functions of the company. His presence on the Audit Committee suggests a role in financial reporting, internal controls, and risk management, while his appointment to the Corporate Governance Committee points to his involvement in matters of board structure, executive compensation, and corporate ethics. Investors can view this as a step towards complete Board integration and oversight.

Jul 28, 2025 8-K

Cigna Group 8-K Report, Executive Changes (Jun 2, 2025)

On June 2, 2025, The Cigna Group (CI) filed an 8-K reporting the appointment of Michael J. Hennigan to its Board of Directors as an independent member, effective the same day. The board made the appointment on May 30, 2025. Hennigan will join the non-employee director compensation program, which was amended and restated effective July 24, 2024 and is described in the 2025 proxy statement. The filing states there is no arrangement under which he was selected and no related-person transactions requiring disclosure under Item 404(a) of Regulation S-K. For investors, this is a routine governance event rather than a material financial development. The filing contains no earnings, guidance, capital allocation, or operational information. Hennigan brings a long energy-sector background: he is Executive Chairman of Marathon Petroleum Corporation and MPLX, previously served as CEO of both, and spent his earlier career at Sunoco and Energy Transfer. The company's stated rationale is his experience in regulated markets, operational excellence, and strategic initiatives. Investors may view the addition as a sign of board diversification in industrial and regulated-market expertise, though its practical impact on Cigna's healthcare strategy is not quantified. The company also stated it will file an amended 8-K once Hennigan's committee assignments are determined. That future filing is the next item to watch for any indication of how the board will use his expertise, such as assignment to a committee overseeing strategy, finance, or compensation.

Jun 2, 2025 8-K

Cigna Group 8-K Report, Regulation FD Disclosure (May 20, 2025)

The Cigna Group (CI) has filed an 8-K report on May 20, 2025, primarily to reaffirm its previously issued 2025 financial outlook. Management expects to confirm that consolidated adjusted income from operations on a per share basis will be at least $29.60. This affirmation comes as company officials are set to participate in investor and analyst meetings over the coming weeks. This filing serves as a reminder of Cigna's financial targets for the year, providing stakeholders with continued confidence in the company's projected performance. Investors should note that the company's outlook was previously detailed in its May 2, 2025 press release and investor presentation, which are available on their Investor Relations website. The report also includes standard forward-looking statement disclaimers, outlining the various risks and uncertainties that could potentially impact actual results.

May 20, 2025 10-Q

Cigna Group Quarterly Report for Q1 Ended Mar 31, 2025

Cigna Group (CI) reported a significant turnaround in its financial performance for the first quarter of 2025, moving from a net loss of $277 million in Q1 2024 to a net income of $1.323 billion, resulting in a diluted EPS of $4.85 compared to ($0.97) in the prior year. This improvement was largely driven by the absence of substantial net investment losses experienced in Q1 2024, which were primarily related to equity security impairments. Total revenues saw a robust 14% increase year-over-year, reaching $65.5 billion, fueled by growth across all segments, particularly a 16% rise in Pharmacy revenues. The company also successfully completed the divestiture of its Medicare Advantage and related businesses to HCSC for an increased purchase price, which is expected to provide additional proceeds in Q4 2025. While operating expenses rose 16%, the strong revenue growth and the elimination of prior-year investment losses contributed to the substantial net income improvement. Cigna also announced a new $6.5 billion credit facility in April 2025, underscoring its strong liquidity position.

May 2, 2025 8-K

Cigna Group 8-K Report, Financial Results (May 2, 2025)

The Cigna Group (CI) reported strong first quarter 2025 results on May 2, 2025, with total revenues rising 14% year over year to $65.5 billion and shareholders' net income of $1.3 billion, or $4.85 per diluted share, compared with a net loss of $0.97 per share a year earlier. Adjusted income from operations was $1.8 billion, or $6.74 per share, up from $6.47 in the prior-year quarter. Growth was driven by Evernorth Health Services, where adjusted revenues rose 16%, largely from specialty pharmacy growth and new and existing client relationships. Cigna Healthcare's adjusted pre-tax income fell 4% as its medical care ratio rose to 82.2% from 79.9%, reflecting higher stop-loss medical costs and the timing of the Medicare divestiture to HCSC, which closed March 19, 2025. Management raised its full-year 2025 adjusted income from operations outlook to at least $29.60 per share, up $0.10, and raised the Cigna Healthcare pre-tax outlook by $25 million to at least $4.125 billion. Evernorth's pre-tax outlook was held at at least $7.2 billion. The guidance implies a Cigna Healthcare MCR of 83.2% to 84.2%. The company repurchased 8.2 million shares for about $2.6 billion year to date through May 1, 2025, and its share count fell to roughly 270 million from 284 million a year earlier. Investors should weigh the headline revenue and earnings growth against the Cigna Healthcare margin compression and the reduction in medical customers, which fell 6% to 18.0 million largely because of the HCSC transaction. The GAAP net income figure was also boosted by a gain on the sale of businesses and reflects large special items, including $215 million for a strategic optimization program and $216 million in integration and transaction costs, which are excluded from adjusted results.

May 2, 2025 8-K

Cigna Group 8-K Report, Material Agreement (Apr 28, 2025)

The Cigna Group (CI) has filed an 8-K reporting several key events, most notably the entry into a new $6.5 billion Revolving Credit and Letter of Credit Agreement. This new facility replaces the Company's prior credit agreement and provides a flexible five-year term with options for expansion and maturity extensions. The agreement includes customary covenants, with a key financial covenant related to a leverage ratio not exceeding 0.60x (or 0.65x post-acquisition). Additionally, the filing announces the resignation of Executive Vice President, Global Chief Information Officer, Ms. Noelle Eder, effective May 16, 2025, which is stated to be for personal reasons and not due to any company disagreement. The report also details the results of Cigna's Annual Meeting of Shareholders, where all director nominees were elected, executive compensation was approved on an advisory basis, PricewaterhouseCoopers LLP was ratified as the independent auditor, and a shareholder proposal for special meeting improvements was not approved.

Apr 28, 2025 8-K

Cigna Group 8-K Report, Executive Changes (Apr 18, 2025)

The Cigna Group (CI) has filed an 8-K report detailing the departure of Eric P. Palmer, Executive Vice President for Enterprise Strategy and President and Chief Executive Officer of Evernorth Health Services. Mr. Palmer's employment officially concludes on April 26, 2025. The filing outlines the terms of his separation agreement, which includes a cash payment of $5.2 million and continued vesting and payout of equity awards valued at approximately $4.8 million. This agreement is structured in accordance with the Company's existing Executive Severance Benefits Plan and Long-Term Incentive Plan.

Apr 18, 2025 8-K

Cigna Group 8-K Report, Corporate Update (Mar 19, 2025)

On March 19, 2025, The Cigna Group (NYSE: CI) completed the previously announced sale of its Medicare Advantage, Cigna Supplemental Benefits, Medicare Part D, and CareAllies businesses to Health Care Service Corporation (HCSC). The filing is a brief Item 8.01 (Other Events) report that attaches the closing press release as Exhibit 99.1. The filing itself discloses no purchase price, financial impact, or updated guidance, so the most important investor takeaway is the portfolio change and the stated use of proceeds rather than new financial figures. Cigna says the divestiture streamlines its portfolio and frees resources for further innovation. Proceeds are to be deployed under the company's existing capital deployment priorities, with the majority expected to go to share repurchases. That capital-return intent is the main per-share consideration for shareholders, though the actual size of buybacks and the sale price are not stated in this document and should be checked against the company's prior announcements and subsequent 10-Q filings. Cigna will keep serving Medicare populations through its Evernorth Health Services unit, and it will continue to provide pharmacy benefit services and other solutions to the divested businesses under transitional services agreements with HCSC for an agreed post-closing period. Management states that coverage and service are not expected to be disrupted for customers, clients, providers, or brokers. The filing also carries standard forward-looking-statement cautions covering integration or separation risks, which could lead to impairment charges.

Mar 19, 2025 8-K

Cigna Group 8-K Report, Executive Changes (Mar 13, 2025)

The Cigna Group's 8-K filing on March 12, 2025, primarily announces significant leadership changes and reaffirms its financial outlook for 2025. Effective March 31, 2025, Brian C. Evanko will step into the role of President and Chief Operating Officer, and Ann M. Dennison has been appointed Executive Vice President and Chief Financial Officer. These appointments are accompanied by updated compensation packages for both executives. The filing also notes the upcoming departure of Eric P. Palmer, Executive Vice President for Enterprise Strategy and President and CEO of Evernorth Health Services, with separation terms to be disclosed later. In addition to the leadership transitions, the company reaffirmed its previously issued 2025 financial guidance. This includes projected consolidated adjusted income from operations of at least $29.50 per share, Evernorth pre-tax adjusted income from operations of at least $7.2 billion, and Cigna Healthcare pre-tax adjusted income from operations of at least $4.1 billion. These reaffirmations provide stakeholders with continued confidence in the company's near-term financial performance expectations, despite the significant organizational adjustments.

Mar 13, 2025 8-K

Cigna Group 8-K Report, Regulation FD Disclosure (Mar 3, 2025)

The Cigna Group (CI) filed an 8-K on March 3, 2025, to reaffirm its previously issued full-year 2025 outlook. Management expects to participate in investor and analyst meetings over the coming weeks, during which they will reiterate their projection of consolidated adjusted income from operations on a per-share basis of at least $29.50. This affirmation provides a degree of certainty for investors regarding the company's expected profitability for the current fiscal year, building on the outlook initially shared on January 30, 2025. The filing emphasizes that adjusted income from operations is a key metric for assessing the underlying performance of Cigna's businesses, although it is a non-GAAP measure and should be considered alongside GAAP figures. Management has also noted the inability to provide a reconciliation of forward-looking adjusted income from operations to GAAP net income due to the unpredictable nature of certain components like investment gains/losses and special items.

Mar 3, 2025 10-K

Cigna Group Annual Report, Year Ended Dec 31, 2024

The Cigna Group's 2024 Form 10-K highlights a year of significant operational activity and strategic repositioning. The company reported total revenues of $247.1 billion, a substantial increase driven primarily by growth in its Evernorth Health Services segment, particularly in Pharmacy Benefit Services. This segment saw a 32% increase in adjusted revenues, fueled by higher utilization and customer growth. However, the Cigna Healthcare segment experienced a decrease in pre-tax adjusted income from operations due to higher medical costs, which are impacting its medical care ratio. The company is in the process of divesting its Medicare Advantage and related businesses to HCSC, expected to close in early 2025, which will reshape its U.S. Healthcare segment. Financially, Cigna Group reported shareholders' net income of $3.4 billion, a decrease from the prior year, largely due to increased net investment losses, notably an impairment related to its VillageMD investment. Adjusted income from operations showed a modest 4% increase, reflecting the strength of Evernorth offsetting some of the pressures in Cigna Healthcare. The company continued its capital return strategy, repurchasing approximately $7 billion of its common stock in 2024 and maintaining its dividend payments, demonstrating a commitment to shareholder value despite the ongoing healthcare industry dynamics and specific business transformations.

Feb 27, 2025 8-K

Cigna Group 8-K Report, Financial Results (Jan 30, 2025)

The Cigna Group reported fourth quarter and full year 2024 results on January 30, 2025, with total revenues up 27% for the year to $247.1 billion, driven mainly by Evernorth Health Services. However, GAAP shareholders' net income fell sharply to $3.4 billion, or $12.12 per share, from $5.2 billion ($17.39 per share) in 2023, primarily due to a non-cash after-tax $2.7 billion ($9.53 per share) investment loss tied to the impairment of VillageMD equity securities. On an adjusted basis, full-year income from operations rose 4% to $7.7 billion ($27.33 per share), but fourth-quarter adjusted income declined 8% to $1.8 billion ($6.64 per share), as Cigna Healthcare's stop loss medical costs pushed its medical care ratio to 87.9% in the quarter. Evernorth remained the growth engine, with adjusted revenues up 32% for the year and adjusted pre-tax income up 9%, supported by client wins, specialty volume growth and Humira biosimilar adoption. Cigna Healthcare adjusted pre-tax income fell 6% for the year and 47% in the fourth quarter. Management is taking corrective actions on stop loss pricing and costs. Capital return remains a priority: the company repurchased 20.9 million shares for about $7.0 billion in 2024, the board added $6.0 billion of repurchase authority (total $10.3 billion), and the quarterly dividend rises 8% to $1.51. For 2025, Cigna guided to adjusted income from operations of at least $7.9 billion, or at least $29.50 per share, with a Cigna Healthcare medical care ratio of 83.2% to 84.2%. The outlook assumes the divestiture of the Medicare businesses to HCSC closes in the first quarter of 2025. Investors should weigh the strong Evernorth growth and capital returns against the stop loss margin pressure and the recurring-looking charges in the GAAP results.

Jan 30, 2025 8-K

Cigna Group 8-K Report, Financial Results (Oct 31, 2024)

The Cigna Group (CI) reported third quarter 2024 results on October 31, 2024, showing strong top-line growth and a reaffirmed full-year adjusted EPS outlook. Total revenues rose 30% year over year to $63.7 billion, driven mainly by Evernorth Health Services, which benefited from large client wins and strong specialty volume growth. Shareholders' net income was $0.7 billion, or $2.63 per share, but this figure absorbed a non-cash after-tax $1.0 billion ($3.69 per share) investment loss tied to VillageMD. Adjusted income from operations was $2.1 billion, or $7.51 per share, up from $6.77 a year earlier. Profitability was mixed beneath the headline. Evernorth's pre-tax adjusted income grew 9%, and Specialty and Care Services was a clear bright spot with 23% growth, while Pharmacy Benefit Services grew only 3% on a 50% revenue increase, reflecting thinner margins from client wins and planned investments. Cigna Healthcare's pre-tax adjusted income fell 4%, as the medical care ratio rose to 82.8% from 80.5%, partly due to business mix and an extra business day. The SG&A expense ratio improved sharply to 5.6% from 7.7%, indicating operating efficiency gains. Total medical customers declined to 19.0 million, mainly from Individual and Family Plans attrition tied to targeted pricing actions, while pharmacy customers grew 22% year to date. Management reaffirmed full-year 2024 adjusted income from operations of at least $28.40 per share, with Evernorth pre-tax adjusted income of at least $7.0 billion, Cigna Healthcare pre-tax adjusted income of at least $4.775 billion, and a Cigna Healthcare MCR guided to 81.7%–82.5%. Investors should note that the outlook excludes future realized investment results and special items, which can materially affect GAAP earnings, and that the VillageMD impairment illustrates the risk in the company's provider-model investments.

Oct 31, 2024 10-Q

Cigna Group Quarterly Report for Q3 Ended Sep 30, 2024

The Cigna Group (CI) reported total revenues of $63.7 billion for the third quarter of 2024, a significant increase of 30% year-over-year, driven by robust growth in its Evernorth Health Services segment. Shareholders' net income for the quarter was $739 million, or $2.63 per diluted share, a decrease of 48% compared to the prior year, primarily due to a substantial impairment loss on equity securities related to its investment in VillageMD. Despite the decline in net income, adjusted income from operations, a non-GAAP measure that excludes special items like investment losses, increased by 5% to $2.1 billion, signaling underlying operational strength. The company's medical customer base saw a slight decrease of 3%, primarily impacting the Individual and Family Plans within the U.S. Healthcare segment. However, Evernorth's Pharmacy Benefit Services and Specialty and Care Services segments demonstrated strong revenue growth, supported by increased prescription drug utilization and customer expansion. The company is also advancing its strategic divestiture of its Medicare Advantage business, expected to close in the first quarter of 2025.

Oct 31, 2024 8-K

Cigna Group 8-K Report, Regulation FD Disclosure (Sep 3, 2024)

The Cigna Group (CI) filed an 8-K on September 3, 2024, to announce that company officials expect to reaffirm their previously issued full-year 2024 outlook. Specifically, Cigna Group anticipates consolidated adjusted income from operations on a per-share basis to be at least $28.40. This reaffirmation suggests that the company is confident in its current performance trajectory and its ability to meet its financial targets for the year. Investors should note that this outlook was initially provided on August 1, 2024, and this filing serves as a confirmation rather than a revision. The company also provided a detailed definition of its non-GAAP measure, "adjusted income from operations," and explained why a reconciliation to GAAP measures is not provided for forward-looking estimates due to inherent uncertainties in certain components like investment results and special items.

Sep 3, 2024 10-Q

Cigna Group Quarterly Report for Q2 Ended Jun 30, 2024

Cigna Group's Q2 2024 report indicates a strong increase in total revenues, driven primarily by a significant rise in pharmacy revenues, reflecting growth from new clients and organic expansion within its Evernorth Health Services segment. While total shareholders' net income saw a decrease year-over-year, largely due to a substantial impairment of equity securities in Q1 2024, the adjusted income from operations showed a healthy increase, demonstrating resilience in underlying business performance. The company's Cigna Healthcare segment experienced moderate revenue growth and improved profitability, supported by higher premium rates and expense management, though a slight decline in medical customers was noted. Liquidity remains robust with significant cash reserves and undrawn credit facilities. The company continues to execute on its capital deployment strategy, including substantial share repurchases and the upcoming sale of its Medicare Advantage businesses, which is expected to yield approximately $3.7 billion. Overall, Cigna appears to be navigating a dynamic healthcare landscape effectively, with core business segments showing operational strength despite market headwinds and one-time financial impacts.

Aug 1, 2024 8-K

Cigna Group 8-K Report, Financial Results (Aug 1, 2024)

The Cigna Group (CI) reported strong second quarter 2024 results on August 1, 2024, with total revenues up 25% year over year to $60.5 billion, driven mainly by large client wins at Evernorth Health Services. Shareholders' net income was $1.5 billion, or $5.45 per share, versus $4.92 a year earlier. Adjusted income from operations, the company's principal profitability measure, rose 5% to $1.9 billion, or $6.72 per share. Growth was broad-based, with Evernorth adjusted revenues up 30% and adjusted pre-tax income up 7%, while Cigna Healthcare adjusted pre-tax income rose 3% on modest 3% revenue growth. The quality of the quarter is nuanced. Pharmacy Benefit Services revenue grew 41%, but its adjusted pre-tax income rose only 3%, and the consolidated adjusted pre-tax margin for Evernorth compressed to 3.3% from 4.0%, reflecting planned investments and a lower-margin revenue mix. Cigna Healthcare's medical care ratio rose to 82.3% from 81.2%, including about $50 million of unfavorable prior-year Medicare Advantage risk adjustment. Corporate and Other losses widened to $451 million on higher interest expense. Management raised its 2024 adjusted income from operations outlook to at least $28.40 per share, with adjusted revenues of at least $235 billion. Capital deployment remained active. Cigna repurchased 14.7 million shares for about $5.0 billion year to date through July 31, 2024, including $3.2 billion under Accelerated Share Repurchase agreements, and the debt-to-capitalization ratio improved to 43.6% from 44.3%. Total customer relationships rose 13% since year-end 2023 to 186.2 million, though total medical customers declined to 19.0 million on targeted pricing actions in Individual and Family Plans, and the full-year medical customer outlook is about 19.3 million. Investors should weigh the strong top-line growth and buybacks against thin Evernorth margins and medical cost pressure.

Aug 1, 2024 8-K

Cigna Group 8-K Report, Executive Changes (Jun 20, 2024)

The Cigna Group (CI) announced a key executive change in its latest 8-K filing, detailing the appointment of Jamie Kates as the new Chief Accounting Officer, effective July 1, 2024. Ms. Kates, a Certified Public Accountant with extensive experience within the company since 2009, will assume the role of principal accounting officer. This appointment signifies continuity and internal promotion, as she has held significant accounting leadership positions, most recently as Vice President, Accounting, overseeing Evernorth Health Services accounting functions. In connection with her new role, Ms. Kates will receive an annual base salary of $400,000, with an incentive plan target of 50% of her base salary for 2024 (prorated) and a $300,000 long-term incentive target for 2025. Investors can view this as a strategic move to maintain stability in financial reporting and governance, leveraging internal talent for a critical financial leadership position.

Jun 20, 2024 8-K

Cigna Group 8-K Report, Regulation FD Disclosure (Jun 6, 2024)

The Cigna Group (CI) has filed an 8-K report on June 6, 2024, affirming its projected full-year 2024 consolidated adjusted income from operations per share of at least $28.40. This affirmation comes as company officials prepare to participate in investor meetings over the coming weeks. The company also highlighted the completion of accelerated share repurchase agreements totaling $3.2 billion, contributing to $4.4 billion in common stock repurchases year-to-date. Cigna Group remains committed to utilizing the majority of its discretionary cash flow for share repurchases throughout the year, indicating confidence in its financial performance and return of capital to shareholders.

Jun 6, 2024 10-Q

Cigna Group Quarterly Report for Q1 Ended Mar 31, 2024

Cigna Group (CI) reported a net loss of $277 million, or -$0.97 per diluted share, for the first quarter of 2024, a significant decline from a net income of $1.3 billion, or $4.24 per diluted share, in the same period last year. This net loss was primarily driven by a substantial $1.8 billion net realized investment loss, largely due to an impairment of equity securities, specifically its investment in VillageMD. Despite the GAAP net loss, the company's adjusted income from operations, a non-GAAP measure, increased by 16% to $1.875 billion, or $6.47 per diluted share, reflecting the underlying operational strength of its Evernorth Health Services and Cigna Healthcare segments. Total revenues saw a significant increase of 23% to $57.3 billion, driven by a 31% surge in pharmacy revenues, largely attributed to the onboarding of Centene. The Cigna Healthcare segment's adjusted revenues grew 4%, supported by higher premium rates. The company also announced its agreement to sell its Medicare Advantage, Medicare Stand-Alone Prescription Drug Plans, Medicare and Other Supplemental Benefits, and CareAllies businesses to Health Care Service Corporation (HCSC) for approximately $3.3 billion, expected to close in Q1 2025. This strategic divestiture, coupled with robust operational performance in its core segments, positions Cigna for future focus and potential capital deployment.

May 2, 2024 8-K

Cigna Group 8-K Report, Financial Results (May 2, 2024)

The Cigna Group's May 2, 2024 8-K furnishes its first-quarter 2024 earnings release and reports a GAAP shareholders' net loss of $277 million, or $0.97 per share, driven by a non-cash after-tax investment loss of $1.8 billion ($6.31 per share) tied to the impairment of its VillageMD equity securities. On an adjusted basis, which management uses as its principal profitability measure, income from operations rose 16% year over year to $1.9 billion, or $6.47 per share, versus $5.41 a year earlier. Total revenues grew 23% to $57.3 billion, largely from Evernorth Health Services' large client wins, and management raised its full-year 2024 adjusted income from operations outlook by $40 million to at least $8.065 billion, or at least $28.40 per share. The quality of the quarter is mixed beneath the headline. Evernorth's adjusted pre-tax margin compressed to 2.9% from 3.6%, reflecting onboarding costs for new clients and a mix shift toward lower-margin pharmacy revenue, while Cigna Healthcare was the clear bright spot, with its medical care ratio improving to 79.9% from 81.3% and pre-tax margin expanding to 10.1%. The company also disclosed a cyber-related claims disruption that inflated Cigna Healthcare net medical costs payable to $5.66 billion, and its debt-to-capitalization ratio rose to 44.3% from 40.1% after debt issuance tied to share repurchases. Investors should also note the pending sale of the Medicare businesses to HCSC, which cleared the Hart-Scott-Rodino waiting period and is expected to close in the first quarter of 2025, and the reorganization of Evernorth into the Pharmacy Benefit Services and Specialty and Care Services operating segments. The filing itself is a routine furnishing of the earnings release under Item 2.02, and the substantive information lies in Exhibit 99.1. The key items for investors are the strength of Cigna Healthcare margins, the Evernorth margin trajectory as large new client relationships ramp, the cyber incident's effect on claims processing, and the company's leverage and buyback activity, including about $3.4 billion of repurchases year to date and a final ASR settlement expected in the second quarter of 2024.

May 2, 2024 8-K

Cigna Group 8-K Report, Shareholder Vote Results (Apr 26, 2024)

This 8-K filing from The Cigna Group reports on the outcomes of its Annual Meeting of Shareholders held on April 24, 2024. The meeting saw high shareholder participation, with over 90% of outstanding shares represented. Key outcomes include the overwhelming approval of director nominees, advisory approval of executive compensation, and ratification of PricewaterhouseCoopers LLP as the independent registered public accounting firm for 2024. However, two shareholder proposals also garnered significant attention and votes against them. Proposal 4, seeking to improve shareholders' rights to call a special meeting, received a substantial number of 'for' votes, indicating shareholder interest in greater governance flexibility. Proposal 5, requesting a report on risks associated with diversity, equity, and inclusion (DEI) efforts, was largely opposed by shareholders, with a vast majority voting against it.

Apr 26, 2024 8-K

Cigna Group 8-K Report, Material Agreement (Apr 26, 2024)

Cigna Group (CI) has filed an 8-K report to disclose the execution of two new revolving credit facilities, replacing its existing credit lines. These facilities include a $5.0 billion Five-Year Revolving Credit Agreement and a $1.5 billion 364-Day Revolving Credit Agreement, totaling $6.5 billion in committed capacity. The agreements provide Cigna with significant liquidity and flexibility, with an option to increase commitments by an additional $1.5 billion, potentially raising the total to $8.0 billion. This move signals proactive financial management and a strategic positioning to support ongoing operations and future growth opportunities. The new credit agreements introduce updated interest rate options, including base rate and term benchmark rate advances, with applicable margins tied to Cigna's senior unsecured credit ratings. Importantly, these agreements include customary covenants and restrictions, notably a financial covenant limiting the leverage ratio (total consolidated debt to total consolidated capitalization) to 0.60:1.00, with a potential increase to 0.65:1.00 following a significant acquisition. This leverage covenant provides a clear financial boundary and demonstrates the company's commitment to maintaining a healthy balance sheet.

Apr 26, 2024 8-K

Cigna Group 8-K Report, Regulation FD Disclosure (Mar 7, 2024)

The Cigna Group (CI) filed this Form 8-K on March 7, 2024 under Regulation FD to furnish a press release tied to its 2024 Investor Day. The company reaffirmed its full-year 2024 outlook of consolidated adjusted revenues of at least $235 billion and adjusted income from operations of at least $28.25 per share, noting that the outlook includes the impact of expected share repurchases and anticipated 2024 dividends. Management expects to reaffirm this guidance during Investor Day and in investor meetings over the following several weeks. No new numerical guidance was introduced, so the outlook is unchanged from the February 2, 2024 release. The main new item for investors is a raised long-term average annual adjusted EPS growth target of 10%-14%. This signals management's confidence in multi-year earnings expansion beyond the 2024 outlook, though the filing does not provide the prior target for comparison or detail the drivers behind the increase. Because long-term targets are forward-looking and not tied to a specific reporting period, investors should weigh them against execution risks, including pricing pressure, medical cost trends, and government program exposure, which the filing flags in its forward-looking statements section. The press release also highlights three product and service initiatives from Evernorth: an EncircleRx financial guarantee for GLP-1 drug costs, a new Evernorth Behavioral Care Group aimed at expanding in-network mental health access, and a planned $0 out-of-pocket Humira biosimilar for eligible Accredo patients. These announcements are strategically relevant to cost containment and pharmacy services, but the filing gives no financial impact estimates for them. The filing also states that the information is furnished rather than filed, so it is not subject to Section 18 liability unless specifically incorporated into another filing.

Mar 7, 2024 10-K

Cigna Group Annual Report, Year Ended Dec 31, 2023

The Cigna Group (CI) reported robust financial performance in its 2023 10-K filing, demonstrating growth across its key segments. The company's Evernorth Health Services segment showed significant revenue expansion, driven by strong performance in its pharmacy benefit services and specialty offerings. Cigna Healthcare also experienced revenue growth, largely due to an increase in medical customers and favorable premium rate adjustments. The company highlighted its strategic focus on innovation and digital capabilities to enhance customer experience and control costs. Significant strategic moves were announced, including the definitive agreement to sell its Medicare Advantage and related businesses to Health Care Service Corporation (HCSC) for $3.3 billion. This divestiture is expected to reshape the company's portfolio, allowing for a greater focus on its core Evernorth Health Services and evolving Cigna Healthcare offerings. The company also continued its commitment to returning capital to shareholders through share repurchases and dividends, signaling financial strength and confidence in its future prospects.

Feb 29, 2024 8-K

Cigna Group 8-K Report, Corporate Update (Feb 15, 2024)

On February 15, 2024, The Cigna Group (NYSE: CI) disclosed that it entered into accelerated share repurchase (ASR) agreements with Deutsche Bank AG and Bank of America, N.A. to buy back $3.2 billion of its common stock under its existing share repurchase program. Cigna prepaid $3.2 billion and received an initial delivery of approximately 7.6 million shares on February 15, 2024. The final number of shares repurchased will depend on the daily volume-weighted average share price over the term of the agreements, less a discount, so the total share count retired is not yet fixed. Final settlement is expected in the second quarter of 2024, and at that point Cigna may receive additional shares, make a cash payment, or deliver shares to the counterparties at its discretion. The repurchase is part of a broader capital return plan. Management said the company is on track to repurchase $5 billion of common stock over the first half of 2024, including this ASR, and expects the majority of discretionary cash flow to be directed to buybacks in 2024. The company had $10.6 billion of remaining authorization under its share repurchase program as of February 13, 2024. Management characterized the transaction as a value-enhancing use of capital that reflects the growth and strength of its businesses. The 8-K is a disclosure of a capital allocation event rather than a financial results report, so it contains no earnings, revenue, or margin data. Investors should weigh the buyback as a signal of management confidence and a driver of per-share value, while recognizing that the final share count and settlement terms remain subject to market prices and contract adjustments.

Feb 15, 2024 8-K

Cigna Group 8-K Report, Material Agreement (Feb 13, 2024)

The Cigna Group (CI) filed an 8-K report on February 13, 2024, detailing the completion of a significant debt offering. The company successfully issued $4.5 billion in aggregate principal amount of Senior Notes across various maturities, ranging from 2029 to 2054, with coupon rates between 5.000% and 5.600%. This offering was made under the company's existing shelf registration statement. The primary purpose of this debt issuance is to fund ongoing capital management activities. Specifically, Cigna intends to use the proceeds to finance its previously announced tender offers for outstanding notes maturing between 2024 and 2030, aiming to repurchase up to $2.25 billion in principal. Any remaining proceeds will be allocated towards the repayment of the 0.613% Senior Notes due in March 2024 and for general corporate purposes, which may include further debt repayment or share repurchases.

Feb 13, 2024 8-K

Cigna Group 8-K Report, Corporate Update (Feb 7, 2024)

The Cigna Group (CI) has announced a significant debt issuance, filing an 8-K report on February 7, 2024, detailing the sale of $4.5 billion in aggregate principal amount of Senior Notes across various maturities. These notes include 5.000% Senior Notes due 2029 ($1 billion), 5.125% Senior Notes due 2031 ($750 million), 5.250% Senior Notes due 2034 ($1.25 billion), and 5.600% Senior Notes due 2054 ($1.5 billion). This debt issuance is strategically aimed at financing its previously announced tender offers for outstanding notes with maturities between 2024 and 2030, up to an aggregate principal amount of $2.25 billion. Any remaining proceeds will be allocated towards the repayment of its 0.613% Senior Notes due 2024 at maturity and for general corporate purposes, which could include further debt repayment or share repurchases. This move indicates a proactive approach to managing its debt profile and capital structure.

Feb 7, 2024 8-K

Cigna Group 8-K Report, Financial Results (Feb 2, 2024)

The Cigna Group's February 2, 2024 Form 8-K (Item 2.02) furnishes its fourth-quarter and full-year 2023 earnings release. Full-year 2023 total revenues were $195.3 billion, up about 8% from $180.5 billion, and GAAP shareholders' net income was $5.2 billion, or $17.39 per share, down from $6.7 billion, or $21.41 per share, in 2022. The decline was driven largely by special items, including a $1.4 billion after-tax loss on the sale of businesses in 2023 versus a gain in 2022. Adjusted income from operations, the metric management emphasizes, rose to $7.4 billion, or $25.09 per share, from $7.3 billion, or $23.36 per share. Fourth-quarter adjusted EPS of $6.79 grew about 35% year over year, reflecting strong contributions from both segments. Segment performance was broadly positive. Evernorth Health Services' full-year adjusted pre-tax income grew 5% to $6.4 billion on 9% adjusted revenue growth, although margins compressed modestly to 4.2% as management invested in technology and client onboarding. Cigna Healthcare was the standout, with full-year adjusted pre-tax income up 9% to $4.5 billion. Its medical care ratio improved to 81.3% from 81.7%, aided by affordability initiatives and pricing discipline, and total medical customers reached 19.8 million, up 10%. Corporate and other operations losses widened to $1.6 billion, mainly because income from divested businesses no longer contributes. Looking ahead, management guided 2024 adjusted income from operations to at least $8.025 billion, or at least $28.25 per share, and adjusted revenues to at least $235 billion. The board also raised the quarterly dividend 14% to $1.40 per share. Investors should weigh the strong operating momentum and capital return against the sizable GAAP charges in 2023, the continued reliance on adjusted (non-GAAP) metrics, and the forward-looking risks flagged in the release, including medical cost trends, pharmacy pricing pressure, and regulatory exposure in government programs.

Feb 2, 2024 8-K

Cigna Group 8-K Report, Corporate Update (Jan 31, 2024)

On January 31, 2024, The Cigna Group (CI) disclosed a definitive agreement to sell its Medicare Advantage, Cigna Supplemental Benefits, Medicare Part D, and CareAllies businesses to Health Care Service Corporation (HCSC) for a total transaction value of approximately $3.7 billion. Cigna expects to record an estimated pre-tax loss of $1.5 billion in net income as of December 31, 2023, primarily reflecting asset write-offs and costs to sell. Importantly, this non-cash-type charge is excluded from adjusted income from operations, so the fourth-quarter 2023 adjusted results are not affected. The transaction is expected to close in the first quarter of 2025, subject to regulatory approvals and customary closing conditions, and carries no financing condition. Management states the deal is expected to be accretive to adjusted EPS in 2025, and that the majority of proceeds will go toward share repurchases, consistent with its capital deployment priorities. Cigna also reaffirmed its 2024 outlook of at least $28 per share in adjusted income from operations and its long-term adjusted EPS growth target of 10% to 13%, with updated guidance to come on the February 2, 2024 fourth-quarter earnings release. Strategically, management frames the divestiture as a move to concentrate capital on Evernorth Health Services and Cigna Healthcare, while Evernorth will continue providing pharmacy benefit services to the sold Medicare businesses under a four-year services agreement. For investors, the key takeaways are the large reported GAAP loss, the clean separation of that loss from adjusted metrics, the buyback-oriented use of proceeds, and the execution risk tied to regulatory approval and a closing timeline more than a year away. The filing's forward-looking statements flag risks including regulatory approval, deal timing, separation difficulties, and Medicare-related government program uncertainty.

Jan 31, 2024